Modulation of rectal cancer stemness, patient outcome and therapy response by adipokines

Vanda Marques; Susana Ourô; Marta B. Afonso; Cecilia M. P. Rodrigues

Ayuda

Modulation of rectal cancer stemness, patient outcome and therapy response by adipokines

Marques, Vanda ^[1] ; Ourô, Susana ^[2] ; Afonso, Marta B. ^[1] ; Rodrigues, Cecília M. P. ^[1]
1. [1] Universidade de Lisboa
  
  Universidade de Lisboa
  
  Socorro, Portugal
2. [2] Surgery Department, Hospital Beatriz Ângelo, Loures, Portugal; Surgery Department, Hospital Beatriz Ângelo, Loures, Portugal
Localización: Journal of physiology and biochemistry, ISSN-e 1877-8755, ISSN 1138-7548, Vol. 79, Nº. 2, 2023, págs. 261-272
Idioma: inglés
Enlaces
- Texto completo 1 (pdf) 2
Resumen
- Response to chemoradiotherapy (CRT) in patients with locally advanced rectal cancer is highly variable. Identification of CRT non-responders and definite accurate biomarkers of response are unmet needs. In turn, adipokines might impact on colorectal cancer development. We hypothesized that imbalance in leptin and adiponectin modulates stemness potential CRT response in rectal cancer. Pre-CRT serum and tissue samples were collected from a cohort of locally advanced rectal cancer patients (n = 33), submitted to long-course CRT and proctectomy. Adiponectin and leptin were measured by ELISA in serum. In tumour biopsies, mRNA expression of stemness-related genes was evaluated by qRT-PCR and transcription factor STAT3 by immunoblotting. Correlations with clinical data and accuracy of potential CRT response biomarkers were evaluated. Carcinoembryonic antigen (CEA) but not leptin or adiponectin distinguished CRT responders from non-responders (p < 0.05). However, higher leptin and lower adiponectin serum levels were associated with positive extramesorectal nodes and extramural vascular invasion. mRNA expression of stemness factors was inversely correlated with adiponectin but positively correlated with leptin. STAT3 phosphorylation presented similar results. CEA levels together with STAT3 activation and OCT4/KLF4 expression accurately identified rectal cancer patients, CRT non-responders (AUROC 0.80; p < 0.05). Adipokines might impact rectal cancer stemness and patient prognosis. The leptin/STAT3 signalling axis provides the rational for a potential biomarker panel that identifies rectal cancer patients who will not benefit from CRT treatment.